Coeptis Therapeutics (NASDAQ:ZSQR) Stock Price Down 7% – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shares traded down 7% during trading on Monday . The stock traded as low as $10.10 and last traded at $10.22. Approximately 155,485 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 201,585 shares. The stock had previously closed at $10.99.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Coeptis Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The company has a fifty day moving average price of $12.01 and a 200 day moving average price of $12.59. The company has a market capitalization of $565.73 million, a P/E ratio of -4.37 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The company had revenue of $0.11 million for the quarter.

Institutional Trading of Coeptis Therapeutics

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. State Street Corp boosted its position in shares of Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the period. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics during the fourth quarter worth approximately $259,000. Yorkville Advisors Global LP bought a new position in Coeptis Therapeutics in the 3rd quarter worth approximately $140,000. Finally, Steward Partners Investment Advisory LLC increased its position in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after acquiring an additional 2,500 shares during the period. 13.88% of the stock is currently owned by institutional investors.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.